Communiqués Processa Pharmaceuticals, Inc. OTC Markets

Actions

PCSA

US74275C4033

Recherche biotechnologique et médicale

Marché Fermé - OTC Markets 21:59:06 01/10/2020			Après clôture 20:47:40
6,100 ^USD	-38,38 %		1,940	-68,20 %

14/08	Processa Pharmaceuticals, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
29/07	Processa Pharmaceuticals, Inc. (NasdaqCM:PCSA) a acquis Vidya Therapeutics, Inc. pour environ 320 millions de dollars.	CI

Communiqués

01/09	Processa Pharmaceuticals to Participate in Upcoming Investor Conferences	AQ
31/07	Processa Pharmaceuticals : Initial Statement of Beneficial Ownership (Form 3)	PU
29/07	PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS	AQ
08/05	Processa Pharmaceuticals : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
12/01	Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference	AQ
05/01	Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study	AQ
17/12	Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer	AQ
05/11	Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025	AQ
07/08/25	Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies	AQ
01/07/25	Processa Pharmaceuticals Provides Portfolio and Business Update	AQ
17/06/25	Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering	AQ
17/06/25	Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate	AQ
16/06/25	Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025	AQ
13/06/25	Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025	AQ
30/05/25	Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting	AQ
15/04/25	Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025	AQ
18/03/25	Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference	AQ
07/02/25	Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference	AQ
30/01/25	Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules	AQ
28/01/25	Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules	AQ
30/10/24	Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results	AQ
02/10/24	Processa Pharmaceuticals : Announces First Patient Dosed in Phase 2 Clinical Trial of NGC Cap in Metastatic Breast Cancer Form 8 K	PU
02/10/24	Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer	AQ
03/09/24	Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September	AQ
28/08/24	Processa Pharmaceuticals Provides Product Pipeline and Financial Update	AQ